Literature DB >> 7075120

Furosemide disposition in cirrhosis.

R K Verbeeck, R V Patwardhan, J P Villeneuve, G R Wilkinson, R A Branch.   

Abstract

Furosemide disposition after rapid intravenous injection (80 mg) was studied in 10 normal healthy subjects and eight patients with cirrhosis and ascites. In the cirrhotic patients the elimination half-life was modestly longer (81.0 +/- 8.0 min and 60.2 +/- 5.8 min). This prolongation was not associated with a difference in systemic clearance (156 +/- 7 ml/min in normal and 142 +/- 16 ml/min in cirrhotic subjects), rather it was a reflection of alterations in furosemide distribution. The steady-state volume of distribution was increased from 8.5 +/- 0.4 l in the healthy subjects to 12.1 +/- 1.3 l in the cirrhotic subjects; estimation in terms of unbound drug indicated an approximately 50% smaller value in cirrhosis. These observations were quantitatively consistent with the increased percentage of furosemide in plasma in the unbound form in the patients (10.2 +/- 1.0%) compared to in the normal subjects (4.0 +/- 0.1%). The 24-hr percentage urinary recovery of unchanged drug (58.8 +/- 2.8% and 53.1 6.5%) and the glucuronide metabolite (17.8 +/- 1.5 and 21.3 +/- 3.4) were on the same order in the normal and cirrhotic groups. The lack of major effects of cirrhosis on furosemide disposition suggests that changes in furosemide diuretic efficacy in such patients is a result of altered dynamic factors rather than altered disposition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075120     DOI: 10.1038/clpt.1982.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 4.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 5.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

6.  Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum.

Authors:  S D Flanagan; L Z Benet
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

7.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.

Authors:  H Ogata; Y Kawatsu; Y Maruyama; K Machida; T Haga
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Furosemide dynamics in conscious rabbits: modulation by angiotensin II.

Authors:  W Homsy; S Marleau; P du Souich
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.